Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Philipp SingerBenjamin K Yee

Abstract

Inhibition of glycine transporter 1 (GlyT1) augments N-methyl-D-aspartate receptor (NMDAR)-mediated transmission and represents a potential antipsychotic drug target according to the NMDAR hypofunction hypothesis of schizophrenia. Preclinical evaluation of GlyT1 inhibiting drugs using the prepulse inhibition (PPI) test, however, has yielded mixed outcomes. Here, we tested for the first time the impact of two conditional knockouts of GlyT1 on PPI expression. Complete deletion of GlyT1 in the cerebral cortices confers resistance to PPI disruption induced by the NMDAR blocker MK-801 (0.2mg/kg, i.p.) without affecting PPI expression in unchallenged conditions. In contrast, restricting GlyT1 deletion to neurons in forebrain including the striatum significantly attenuated PPI, and the animals remained sensitive to the PPI-disruptive effect of MK-801 at the same dose. These results demonstrate in mice that depending on the regional and/or cell-type specificity, deletion of the GlyT1 gene could yield divergent effects on PPI.

References

Mar 1, 1992·Archives of General Psychiatry·D L BraffM A Geyer
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J LermaM V Bennett
Jan 1, 1990·Advances in Experimental Medicine and Biology·R DingledineC J McBain
Jan 1, 1990·Neuroscience and Biobehavioral Reviews·S Puglisi-AllegraS Cabib
Apr 1, 1969·Journal of Comparative and Physiological Psychology·G BucklandJ R Ison
Mar 1, 1993·Pharmacology, Biochemistry, and Behavior·N R Swerdlow, M A Geyer
Apr 1, 1997·Progress in Neurobiology·S Puglisi-Allegra, S Cabib
Feb 25, 1998·Behavioural Brain Research·M Koch, H U Schnitzler
May 8, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·N PatelR Hitzemann
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·R BergeronR W Greene
Dec 24, 1998·Journal of Neurophysiology·A J BergerP Ascher
Apr 4, 2000·Biological Psychiatry·A ParwaniJ P Rotrosen
Apr 6, 2001·Clinical Neuropharmacology·S I DeutschJ Mastropaolo
Sep 11, 2001·Psychopharmacology·M FendtJ S Yeomans
Dec 12, 2002·Molecular Psychiatry·M A GeyerR Paylor
Mar 21, 2003·Nature·Yi NongMichael W Salter
Aug 1, 1965·Journal of Comparative and Physiological Psychology·H S HOFFMAN, J L SEARLE
Oct 24, 2003·Molecular and Cellular Neurosciences·Claude SchweizerBernhard Lüscher
May 6, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Benjamin K YeeJoram Feldon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here